ClinicalTrials.gg
RecruitingNCT07578675AN-CNAUpdated Sep 18, 2026

Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS

An observational study in Aplastic Anemia, Myelodysplastic Syndromes and Autoimmune Hemolytic Anemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
323
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Anemia is a global public health concern and is closely linked to dysfunction of brain cognitive neural networks, a key mechanism underlying cognitive impairment. Such deficits-including declines in memory, learning, processing speed, and executive function-reduce daily living abilities and increase risks of falls and depression.

Functional near-infrared spectroscopy (fNIRS) enables real-time monitoring of oxygenated and deoxygenated hemoglobin fluctuations, reflecting brain network function. This study aims to identify affected neural network regions in anemic patients and visualize connectivity changes using heatmaps and arc-based mapping. The findings will support early detection of cognitive impairment and guide precise clinical interventions, ultimately informing individualized treatment strategies to enhance therapeutic outcomes and quality of life.

02

Conditions studied

  • Aplastic Anemia
  • Myelodysplastic Syndromes
  • Autoimmune Hemolytic Anemia
  • Functional Near-Infrared Spectroscopy
03

In context

Anemia, Aplastic

371 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

This study's planned enrollment of 323 is above the median of 100 across 64 observational studies indexed under Anemia, Aplastic.

Browse Anemia, Aplastic studies →

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 410 studies on the registry; 291 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with anemia who were hospitalized for the first time during the period from 2026 to 2028.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of anemia
  • First hospitalization
  • Male or female, aged 18-65 years
  • Willing and able to comply with the requirements for this study and written

Exclusion criteria

Exclusion Criteria:

  • History of psychiatric illness
  • History of severe brain disease
  • Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
323 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Concentration changes in oxygenated hemoglobin (HbO) and de-oxygenated hemoglobin (HbR)

    Functional Near Infrared Spectroscopy (fNIRS) is a non-invasive brain imaging modality, that can be used to measure HbO and HbR concentrations.

    Time frame: Patients will be assessed within 48 hours of admission.

  2. Cognitive Function Assessment

    Montreal Cognitive Assessment (MoCA) is used to assess cognitive function in patients, with higher total scores indicating better cognitive function. The total score range is 0 to 30.

    Time frame: Patients will be assessed within 48 hours of admission.

Secondary outcomes

  1. Anxiety symptoms

    Hamilton anxiety scale(HAMA) is used to examine anxiety in AIHA patients, with higher total scores indicate more severe anxiety symptoms. The total score range is 0-56.

    Time frame: Patients will be assessed within 48 hours of admission.

  2. Depression symptoms

    Hamilton depression scale(HAMD) is used to examine depression in AIHA patients, with higher total scores indicate more severe depression symptoms. The total score range is 0-52.

    Time frame: Patients will be assessed within 48 hours of admission.

  3. Sleep quality

    The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality, with a higher global score indicating poorer sleep quality. The global score range is 0-21.

    Time frame: Patients will be assessed within 48 hours of admission.

  4. Physical fatigue

    It measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale. The total possible score is 0-52 points, with higher scores indicating less fatigue.

    Time frame: Patients will be assessed within 48 hours of admission.

  5. Appetite condition

    Simplified Nutritional Appetite Questionnaire (SNAQ) is used to assess appetite in patients, with higher total scores indicating better appetite. The total score range is 4 to 20.

    Time frame: Patients will be assessed within 48 hours of admission.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07578675
Collaborators
Tianjin University
Responsible party
Sponsor
First posted
May 11, 2026
Start date
Oct 11, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

ZheXiang Kuang, MSN
Contact
kuangzhexiang@ihcams.ac.cn
13920361752
Xiao Yu, Undergraduate
Contact
yuxiao@ihcams.ac.cn
18722218448

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion